Navigation Links
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
Date:10/2/2008

QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that it has entered the second stage of patient recruitment for its Phase 2 trial in ovarian cancer with AEZS-108, a luteinizing hormone-releasing hormone (LHRH) agonist linked to doxorubicin. The decision to enter the second stage of patient recruitment was taken following recent first stage data reporting two partial responses (PR) among patients with a diagnosis of platinum-resistant ovarian cancer. The trial is part of a Phase 2 program in gynaecological cancers for which patient enrolment began in December 2007. The open-label, non-comparative multi-center Phase 2 program will treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary endpoint for the program is the partial or complete tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. The program is being conducted in 15 centers in Europe under the supervision of lead investigator, Prof. Gnter Emons, M.D., of the Georg-August-University, Institute of Gynaecology and Obstetrics in Gttingen, Germany.

Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris commented, "We are encouraged by the early signal of potential efficacy of our lead oncology compound, AEZS-108, for patients suffering from ovarian cancer. We believe that specifically targeting LHRH-receptor expressing tumors using doxorubicin is key to achieving increased clinical benefit for these patients. Finally, we look forward to disclosing full results during the next fe
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
3. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
4. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
5. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
6. Genmab Reaches Milestone in Ofatumumab Collaboration
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. , Sept. 1, 2015 ... Care Management (CCM) and Drug Adherence m Health ... help automate the process of non face-to-face monitoring ... "With this new release of our apps, doctors ... management services along with our ONCHIT certified Physician, ...
(Date:9/1/2015)... September 1, 2015 The ... the basis of sectors, products & services and ... coupled with the increasing demand of advanced drugs ... to propel the growth for bioinformatics market. The ... efficiently is known as bioinformatics. Decreasing cost of ...
(Date:9/1/2015)... -- In nur zwei Jahren nach dem Erreichen ... Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese Steigerung ... Markt der injizierbaren Medikamente und das ... SHL wieder. Foto - http://photos.prnewswire.com/prnh/20150820/259886 ... Design und Herstellung automatischer Injektoren und Pen-Injektoren und ...
Breaking Medicine Technology:SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2
... 11, 2011 As part of its re-branding initiative, ... website www.xeridiem.com .  Winner of MD+DI,s 2011 Medical ... Supplies Xeridiem has been recognized as an industry leader ... invasive medical devices. For over 25 years, Xeridiem has ...
... Inc. (OTC: HEWA), a leading VIPPS-accredited, retail, mail-order ... have among the lowest total prices for four ... The study was conducted by 43,739 Consumer ... and speed.  "Our national study of prices for ...
Cached Medicine Technology:Consumer Reports Finds HealthWarehouse.com Has Lowest Total Price for Lipitor, Nexium, Plavix, and Singulair 2
(Date:9/1/2015)... ... ... The Journal of Pain Research has published the original research ... corresponding author Mr Christopher Malone says “Migraine headache is a painful chronic condition affecting ... understand how migraine headaches impact the lives of migraineurs. We asked migraineurs about a ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced its annual Light it Red for Lymphoma awareness initiative, the nation’s ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Philanthropic giving in ... of societal issues and needs. Money for Good 2015, released today by Camber Collective, ... There’s an annual potential to mobilize up to $22B in new philanthropic giving and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly ... Society for Dermatologic Surgery, according to a new survey that also offers insight ... Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, ... strongly maintaining her firm’s success in the hair care and distribution industry through ... tour, Ellis will be providing “Look and learn” live demonstrations, as well as ...
Breaking Medicine News(10 mins):Health News:Migraine, treatment, comorbidities, and quality of life published by Dove Medical Press 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
... 20, 2011) When two adjacent discs in the low ... or other symptoms, replacement with artificial discs can be a ... data from a randomized, multicenter trial recently published in the ... studies have compared single-disc replacement with fusion but this is ...
... All children should be screened for high cholesterol when they,re ... the National Lipid Association. The group also urges that ... elevated cholesterol be screened for cholesterol with a simple blood ... people know if a history of high cholesterol runs in ...
... (HealthDay News) -- People who have psoriasis and hypertension are ... more medications to control it, a new study suggests. ... causes itchy, thickened, dry, red patches on the skin. ... 835 patients who had psoriasis and hypertension. Their cases were ...
... as follows: SESSION I / Monday, May 23 ... Rates of Acute Coronary Syndrome Patients in Real World Clinical ... Gandhi SK2, Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, ... Wilmington, Del. SESSION II / Tuesday, May 24 ...
... Aage Moller of UT Dallas is known throughout the world ... But back at The University of Texas at Dallas, he,s ... Moller received the President,s Teaching Excellence Award for Tenure-Track ... was selected from among more than 100 eligible faculty members ...
... provides evidence for significant differences between new and old ... a cheap, rapid and effective way to monitor the ... preservatives, blood stored in banks continues to age, resulting ... subsequent changes to cell properties and function. There ...
Cached Medicine News:Health News:2-year results: Artificial disc a viable alternative to fusion for 2-level disc disease 2Health News:Experts Say Cholesterol Screenings Should Start in Childhood 2Health News:Psoriasis, High Blood Pressure May Be Linked 2Health News:HealthCore presents ISPOR poster sessions 2Health News:UT Dallas' Moller receives teaching award 2Health News:Research provides insight into quality of stored blood used for transfusions 2Health News:Research provides insight into quality of stored blood used for transfusions 3
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: